Beiersdorf is “strengthening” its dermatology business with a new Eucerin innovation for acne-prone skin based on more than two decades of microbiome research.
Eucerin’s Dermopure Clinical Probiom8 launch is formulated with patented cosmetic active ingredient TopiC.A, which the German beauty giant said uses viable, skin-identical probiotics to restore the natural balance of the skin microbiome.
TopiC.A contains two viable, naturally occurring strains of bacteria in a dormant state, which are activated as part of the dermatological brand’s Probiom8 skin care routine and support the natural balance of the skin microbiome.
Beiersdorf claimed that while other solutions on the market address microorganisms indiscriminately, its patented ingredient TopiC.A relies on specifically selected strains of bacteria that naturally occur on healthy-looking skin.
“Dermopure Clinical Probiom8 is far more than a product launch,” said Burcu Andreae-Nehlsen, Brand President Derma & Healthcare at Beiersdorf.
“It is proof of how we translate long-term research investments into relevant cosmetic solutions for our consumers.
“For Eucerin, this innovation opens up new perspectives in a market that affects millions of people worldwide and is one of the largest skin care categories.”
Tickets are now available for the 25th anniversary of the Pure Beauty Awards, taking place on 15 October 2026 at the Grosvenor House Hotel in London, UK. Join the beauty industry for an evening of recognition and celebration as this year’s winners are revealed. Click here to secure your place.
The global market for acne-prone skin care products grew approximately 8.8% from 2020 to 2025, according to research from market analyst Euromonitor, reaching sales of €4.6bn in 2025.
Beiersdorf said it is leveraging years of research to address this common skin care need worldwide and cement its position even further in the derma beauty market.
Eucerin’s Dermopure Clinical Probiom8 technology is based on 20 years of microbiome research, more than 120 studies, a broad patent portfolio and additional scientific expertise gained via Beiersdorf’s 2022 acquisition of life science company S-Biomedic.
“For us, innovation begins with understanding the skin as thoroughly as possible,” said Dr Gitta Neufang, Chief R&D Officer at Beiersdorf.
“Our credo is: learn from the skin to create skin care products that work in harmony with its natural biology.
“Research into the skin microbiome has fundamentally expanded our knowledge.
“It opens up new perspectives on how skin care can be developed in the future.
“The skin microbiome is one of the most exciting fields of research in dermatology and an important building block for the next-generation of scientifically-based skin care.”
Beiersdorf is also working hard to strengthen its position in the field of longevity beauty.
The company has just unveiled a new eye serum under its skin care brand Nivea which combines longevity science with cryogenic technology.
Related content:
- Nivea extends longevity offering with epigenetics eye serum featuring cryogenic technology
- Beiersdorf eyes acquisitions to reduce reliance on Nivea
- Nasal microbiome: Why research into the nose-brain axis will take beauty by storm
- Beiersdorf aims to make longevity skin care ‘accessible’ with Nivea innovation
- Unilever on uncovering the mysteries of the microbiome
- Beiersdorf cuts sales guidance as Nivea turnaround ‘remains too isolated’
